1. Home
  2. MKTW vs GRDX Comparison

MKTW vs GRDX Comparison

Compare MKTW & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MarketWise Inc.

MKTW

MarketWise Inc.

HOLD

Current Price

$17.14

Market Cap

39.7M

Sector

Technology

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$4.46

Market Cap

39.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MKTW
GRDX
Founded
1999
N/A
Country
United States
United Kingdom
Employees
N/A
2
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.7M
39.3M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
MKTW
GRDX
Price
$17.14
$4.46
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$20.00
N/A
AVG Volume (30 Days)
11.1K
123.5K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
10.20%
N/A
EPS Growth
1183.33
N/A
EPS
N/A
N/A
Revenue
$512,403,000.00
N/A
Revenue This Year
$1.52
N/A
Revenue Next Year
$4.55
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.49
$1.87
52 Week High
$21.74
$6.93

Technical Indicators

Market Signals
Indicator
MKTW
GRDX
Relative Strength Index (RSI) 52.55 44.89
Support Level $16.17 $2.16
Resistance Level $17.60 $5.30
Average True Range (ATR) 0.53 0.64
MACD 0.01 -0.25
Stochastic Oscillator 57.58 4.78

Price Performance

Historical Comparison
MKTW
GRDX

About MKTW MarketWise Inc.

Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: